 |
|
|
|
|
Iowa Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2022 replacing IowaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
NewLink Genetics Corporation
| | | | | Phone: | (515) 296-5555 | | Fax: | (515) 296-3520 | | Year Established: | 1999 | | Employees: | 82 | | Ticker: | NLNK | | Exchange: | NASDAQ | | Main Contact: | Jack Henneman, CFO | | | | Other Contacts: | Eugene Kennedy, M.D., CMO
Gabriela R Rossi, Ph.D., VP, Biologics Development
Brian Wiley, CCO
Mario Mautino, Ph.D., VP, Drug Discovery & IP
Lisa DeLuca, PhD,, VP, Regulatory Affairs
Nicholas N. Vahanian, M.D., Co-Founder & President
Charles J. Link, Jr., M.D., Co-Founder, Chairman, CEO & CSO
| | | | Company Description | | NewLink Genetics (formerly BioProtection Systems Corp.) is a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians. NewLink's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a wide range of oncology indications. NewLink's product candidates are designed with an objective to harness multiple components of the innate immune system to combat cancer, either as a monotherapy or in combination with current treatment regimens, without incremental toxicity. NewLink's lead product candidate, algenpatucel-L (HyperAcute Pancreas) cancer immunotherapy is being studied in a Phase 3 clinical trial in surgically resected pancreatic cancer patients (patient information is available at http://www.pancreaticcancer-clinicaltrials.com) under a Special Protocol Assessment with the U.S. Food and Drug Administration. NewLink and its collaborators have completed patient enrollment for a Phase 2 clinical trial evaluating its tergenpumatucel-L (HyperAcute Lung) cancer immunotherapy product candidate for non-small cell lung cancer and is now recruiting patients in a Phase 2B/3 clinical trial in this indication. NewLink has completed patient enrollment in a Phase 2 clinical trial for its HyperAcute Melanoma cancer immunotherapy product candidate. NewLink also is developing indoximod (NLG8189 or D-1MT), a small molecule, orally bioavailable product candidate from NewLink's proprietary indoleamine (2, 3) dioxygenase, or IDO, pathway inhibitor technology. Through NewLink's collaboration with the National Cancer Institute, NewLink is studying indoximod in various chemotherapy and immunotherapy combinations in two Phase 1B/2 safety and efficacy clinical trials. | |
|
|
|
|
|
|
|
